Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma

Jiang, Li; Hou, Yu; Cai, Xiao-bei; Liu, Bin

doi:10.3748/wjg.v22.i15.4034

Cited by 43 publications

(35 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer staging and postoperative treatment varied in patients with or without PVI. Currently, clinical trials have been conducted to validate various techniques for example surgical resection, transcatheter arterial chemoembolization (TACE), hepatic arterial infusion chemotherapy, radioembolization and sorafenib for the treatment of HCC [27–29]. Besides, attention has been paid to understand the promoting factors of PVI and corresponding mechanisms [22].…”

Section: Discussionmentioning

confidence: 99%

Vasculogenic mimicry in hepatocellular carcinoma contributes to portal vein invasion

Chen

Zhang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Portal vein invasion (PVI) is common in hepatocellular carcinoma (HCC) and largely contributes to tumor recurrence after radical tumor resection or liver transplantation. Vasculogenic mimicry (VM) was an independent vascular system lined with tumor cells and associated with poor prognosis of HCC. The present study was conducted to evaluate the relationship between VM and portal vein invasion. A total of 44 HCC cases receiving anatomic liver resection were included in the study and were divided into groups with and without PVI. The prevalence of VM in each group was examined by CD34-PAS dual staining. The regulatory molecules of VM formation such as Notch1, Vimentin and matrix metalloproteinases (MMPs) were investigated by immunohistochemical staining. Analysis was performed to explore the association of PVI, VM and the VM regulatory molecules. PVI was found in 40.91% (18/44) cases and VM was found in 38.64% (17/44) cases in total samples. The incidence of VM was 72.22% (13/18) in PVI group while it was 15.38% (4/26) in non-PVI group (P<0.001), VM formation was positively correlated with PVI (r=0.574, P<0.001). The VM forming regulatory molecules such as Notch1, Vimentin, MMP-2 and MMP-9 were found to be correlated with PVI in HCC patients. Taken together, our results suggested that VM formation, alone with its regulatory molecules, is the promoting factor of PVI in hepatocellular carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Vasculogenic mimicry in hepatocellular carcinoma contributes to portal vein invasion

Chen

Zhang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Several studies have reported that perioperative treatment with hepatectomy could improve the prognosis of HCC patients with PVTT. Previous studies have reported the outcomes of combination treatment based on surgical resection for HCC patients with PVTT (Table ) . The MST and 1‐year OS rate after combination treatment ranged from 11.5 to 37 months and from 46.8% to 100%, respectively.…”

Section: Surgical Resection Combined With Multidisciplinary Treatmentmentioning

confidence: 99%

“…Previous studies have reported the outcomes of combination treatment based on surgical resection for HCC patients with PVTT (Table 2). 24,[33][34][35][36][37][38][39][40] The MST and 1-year OS rate after combination treatment ranged from 11.5 to 37 months and from 46.8% to 100%, respectively. In a randomized controlled trial, Peng et al reported that estimated 1-, 3-and 5-year survival rates were better in the TACE after surgical resection group (50.9%, 33.8%, and 21.5%) than in the surgical resection alone group (33.3%, 17.0%, and 8.5%).…”

Section: Surgical Resection Combined With Multidisciplinary Treatmentmentioning

confidence: 99%

Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus

Sakamoto

2017

Hepatology Research

View full text Add to dashboard Cite

The Barcelona Clinic Liver Cancer staging system recommends a tyrosine kinase inhibitor (sorafenib) as standard therapy in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). Sorafenib has been shown to prolong median overall survival (OS) by approximately 3 months in advanced HCC patients with PVTT (8.1 vs. 4.9 months). However, its clinical effectiveness is still controversial and standard treatment with sorafenib is not established in Japan. Surgical resection is considered a potentially curative treatment and provides an acceptable outcome for carefully selected patients. The surgical mortality rate in patients with PVTT who receive surgical resection ranges from 0% to 10%. The median survival time and 1-year OS rate in HCC patients with PVTT who undergo surgical resection have been found to range from 8 to 22 months and 21.7% to 69.6%, respectively. But improvement in therapeutic outcome is difficult with surgical treatment alone. Combination treatment in conjunction with such methods as transarterial chemoembolization, hepatic artery infusion chemotherapy, and radiotherapy has been found to improve the prognosis (median survival time, 11.5-37 months; 1-year OS rate, 46.8-100%). Yet, many problems remain, such as surgical indications and surgical techniques. After resolving these points, a multidisciplinary strategy based on surgical treatment should be established for advanced HCC with PVTT.

show abstract

“…Prevention of postoperative recurrence is the focus of postoperative management in HCC with TT in the IVC and RA. Measures to prevent postoperative recurrence include postoperative oral sorafenib administration (30)(31)(32) and adjuvant TACE (33,34).…”

Section: Treatmentmentioning

confidence: 99%

Diagnosis, treatment and prognosis of hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus (Review)

Xia

Zhang

2020

Oncol Lett

View full text Add to dashboard Cite

Although tumor thrombus (TT) infringement of the inferior vena cava (IVC) and right atrium (RA) is rarely observed in hepatocellular carcinoma (HCC), the prognosis for this condition is extremely poor, with a median survival time of several months, given that the condition is often diagnosed at an advanced tumor stage or combined with multiple systemic metastases. Furthermore, there is no established effective treatment for the condition. However, some investigators insist that active treatment, including surgery, chemotherapy (systemic or intra-arterial), radiation therapy, best supportive care or a combination of these, may help prolong overall survival time in these patients. The management of patients with advanced HCC and a TT extending into the RA and IVC is extremely difficult and risky. To this end, the present review assessed the literature on the clinical features and treatments of this condition in recent years, with the aim of providing assistance for clinical work.

show abstract

Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma

Abstract: Sorafenib after SR was well-tolerated. Patients who received sorafenib after SR had better outcomes compared to patients who received only SR.

Cited by 43 publications

References 40 publications

Vasculogenic mimicry in hepatocellular carcinoma contributes to portal vein invasion

Vasculogenic mimicry in hepatocellular carcinoma contributes to portal vein invasion

Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus

Diagnosis, treatment and prognosis of hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus (Review)

Contact Info

Product

Resources

About